India Glycols LtdQ1 FY27
India Glycols Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹1,190P/E: 24.2Market Cap: ₹7.7K CrSector: Beverages
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3Future growth expectations for India Glycols Limited (IGL) in sales/revenue/volumes include:
- Potable Spirits segment expects revenue growth to exceed volume growth due to premiumization and new high-margin offerings in deluxe whisky, semi-premium vodka, and white spirits.
- IMFL revenue expected to be over 30% of Potable Spirit revenue in FY27.
- Doubling of potable spirits volume planned for FY27 with deeper state penetration and new brand launches.
- Spirits business targeting EBITDA over INR 500 crores in FY27, aiming for INR 1,000 crores in 4-5 years.
- Chemicals business shows 25% YoY revenue growth; pipeline strong in performance chemicals.
- ENNature Bio Pharma targeting INR 130-150 crores EBITDA over next 4-5 years with growth in nicotine and nutraceuticals.
- Business restructuring to enhance focus and investor clarity, aiding growth.
- Debt reduction expected to improve profitability and support expansion.
Growth fueled by geographic expansion, premiumization, new brands, and operational efficiencies.
Margin guidance
Category 3- →India Glycols aims for an EBITDA in excess of INR 500 crores for FY27, with INR 120 crores already delivered in Q1.
- →The company expects revenue and volume growth in potable spirits driven by premiumization, new launches in deluxe whiskey and semi-premium vodka, and expansion into new states.
- →Target to become debt-free by FY28 with EBITDA projected to exceed INR 1,000 crores in 4-5 years.
- →Ennature Bio Pharma aspires to achieve INR 130-150 crores EBITDA in the next 4-5 years, supported by product expansion and capacity growth.
- →Specialty chemicals business aims to improve gross margins to about 30% over 5-6 years.
- →Overall, strong double-digit growth in gross revenue, EBITDA, and PAT (PAT up 32% in Q1 FY27).
- →Premiumization and operational efficiencies expected to drive earnings growth and margin improvement.
Track India Glycols Ltd — get its next earnings analysis in your feed
Fundraise plans
- →The transcript does not explicitly mention any current or planned fundraising through debt or equity.
- →There is mention of debt reduction: finance costs declined from INR 45 crores in Q1 FY26 to INR 25 crores in Q1 FY27 due to debt reduction.
- →The company is targeting to become a debt-free company from FY28 onwards.
- →No specific plans for new debt or equity fundraising have been disclosed in the provided pages.
- →The management emphasizes profitable growth and reducing debt rather than seeking new borrowings.
- →Any capital expenditure mentioned is modest and internally funded (e.g., INR 5-20 crores for NSU segment capex).
Order book
The transcript does not explicitly mention current or expected order book or pending orders details for India Glycols Limited. However, relevant points related to business outlook and growth include:
- Ennature Bio Pharma has a strong order pipeline supporting 26% growth in Thiocolchicoside sales.
- The Spirits business is targeting healthy double-digit volume growth driven by new offerings and deeper penetration.
- The joint venture performance is steady, with increased sales and exports to Clariant customers worldwide.
- The company is focusing on customer and product expansion across multiple segments.
- No specific quantitative data on order book or pending orders is disclosed in this transcript.
For detailed order book or pending orders data, the management has requested investors to reach out via email for personalized responses.
Capex plans
Yes- →For the NSU (Nutraceuticals and Specialty Uses) segment, incremental capex of approximately INR 5-20 crores is planned for the current year.
- →No major large-scale capex (like INR 400-500 crores plant) is expected in the next 2 years unless new technologies are pursued.
- →Modular expansion approach will be followed as business grows.
- →The core plant expansion till now involved around INR 50-60 crores investment, utilizing some existing assets.
- →Investment plans include scaling up capacity, new product introductions, and customer engagement to grow NSU business.
- →Renewable materials and bio-based chemicals innovations continue but specific future investments were not disclosed.
- →Potable Spirits segment expects growth driven by new brand launches, geographic and channel expansion, and premiumization.
- →Overall, capex is moderate and focused on incremental scaling and new product development over the near term.
How does India Glycols Ltd rank vs peers in Beverages?
Pro feature1India Glycols Ltd
Rev 3Mar 3
See full Beverages sector rankings
How does India Glycols Ltd rank in Beverages?
Compare India Glycols Ltd against every Beverages company (Q1 FY27) on revenue, margins and earnings-call signals.